It has been four years this week (June 23, 2016) since UK voters approved a referendum for the UK to exit the EU (i.e., Brexit). Whether the UK will have…
How was the global pharmaceutical industry performing before the novel coronavirus (COVID-19) pandemic, and what now is the near- and long-term impact on industry fundamentals and growth projections? An upcoming…
Emerging pharma companies play an important role in new product development. Which companies are making strong plays based on recent high-value partnering deals? DCAT Value Chain Insights’ Top 10 highlights…
Private Equity’s Growing Role in the Biopharma Industry
The bio/pharma industry, both bio/pharma companies and CDMOs/CMOS, has been a target of increased investment by private-equity (PE) firms. A recent analysis by Bain & Company examines financing trends and…
CDMOs Step Up to the COVID Challenge but Must Prepare for Uncertain Future
CDMOs have met the operational challenges presented by the novel coronavirus (COVID-19) pandemic to date, but what is the near-term and long-term impact as biopharma companies re-access drug-development projects? The…
Driven by growth in oncology drugs, high-potency manufacturing is an active area of investment by CDMOs/CMOs. Which CDMOs/CMOs are making investments? DCAT Value Chain Insights rounds up key recent expansions…
Oncology Pharma Market: Immunotherapies on the Rise
Immunotherapies represent a growing sector in the global oncology pharmaceutical market. Now led by Merck & Co.’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), immunotherapies by Roche and AstraZeneca are…
CFOs Weigh in on Companies’ Work Return Amid COVID-19
As lockdown measures to COVID-19 are slowly being lifted globally, how are companies responding? A recent PwC survey of nearly 870 CFOs in 24 territories examines companies’ plans with respect…
DCAT Benchmarking Study Provides Insight into Supply-Chain Challenges
How are executives from biopharma companies, CDMOs/CMOs, and suppliers confronting real and potential risks in the wake of new trade policies? A recent DCAT Benchmarking study, conducted prior to COVID-19,…
Following AbbVie’s $63-billion acquisition of Allergan, which closed earlier this month (May 2020), the new AbbVie, reflecting the combined companies, has projected revenues of $50 billion. DCAT Value Chain Insights…
